NCT04819685 is a Phase 4 clinical trial of KANG FU PEN in Cervical Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04819685?

NCT04819685 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04819685?

Interventions in NCT04819685: KANG FU PEN.

What condition does NCT04819685 study?

NCT04819685 studies Cervical Cancer, Radiotherapy Side Effect, Radiotherapy; Complications.

Is NCT04819685 still recruiting?

NCT04819685 is currently status unknown. Last updated 29 March 2021.

Last reviewed 2021-03-29 · How we verify

NCT04819685

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury

Status unknown Phase 4 Last updated 29 March 2021

What this trial tests

Phase 4 trial testing KANG FU PEN in Cervical Cancer in 520 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
1 March 2023

1 March 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	520
Start date	1 March 2021
Primary completion	1 March 2023
Estimated completion	1 March 2025
Sites	1 location across China

Drugs / interventions tested

KANG FU PEN — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →
Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
Radiotherapy; Complications — all drugs for Radiotherapy; Complications →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 65, female only, with Cervical Cancer or Radiotherapy Side Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of 520 cases will be randomly divided into Kang Fu Pen (liquid dressing) enema intervention group (experimental group) and non-enema intervention group (control group), according to the ratio of 1:1.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multicenter, Randomized, Open-label, Prospective Trial.
Zhu J, Li X, Huang M, Zhu H, et al · · 2024 · cited 7× · PMID 38705489 · DOI 10.1016/j.ijrobp.2024.04.070
Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets.
Wei W, Ren Y, Lan J, Yi J, et al · · 2026 · PMID 41507636 · DOI 10.1186/s43556-025-00358-4

Verify or expand the search:

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04819685 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 29 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04819685.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing